Wall Street analysts expect that Seres Therapeutics Inc (NASDAQ:MCRB) will report sales of $6.82 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Seres Therapeutics’ earnings. The highest sales estimate is $9.26 million and the lowest is $3.00 million. Seres Therapeutics posted sales of $10.63 million during the same quarter last year, which would indicate a negative year over year growth rate of 35.8%. The firm is expected to issue its next earnings results on Wednesday, March 4th.
On average, analysts expect that Seres Therapeutics will report full year sales of $34.03 million for the current fiscal year, with estimates ranging from $29.88 million to $36.14 million. For the next fiscal year, analysts expect that the business will report sales of $37.78 million, with estimates ranging from $18.70 million to $53.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. The business had revenue of $7.03 million during the quarter, compared to analysts’ expectations of $6.69 million.
A number of large investors have recently modified their holdings of MCRB. Squarepoint Ops LLC acquired a new stake in Seres Therapeutics in the third quarter valued at $215,000. Barclays PLC boosted its position in shares of Seres Therapeutics by 36.5% during the 3rd quarter. Barclays PLC now owns 19,737 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 5,278 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Seres Therapeutics by 72.3% during the 3rd quarter. California State Teachers Retirement System now owns 56,844 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 23,862 shares in the last quarter. State Street Corp increased its holdings in shares of Seres Therapeutics by 24.9% in the 3rd quarter. State Street Corp now owns 573,351 shares of the biotechnology company’s stock valued at $2,299,000 after acquiring an additional 114,375 shares during the last quarter. Finally, Voya Investment Management LLC increased its holdings in shares of Seres Therapeutics by 35.1% in the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 3,555 shares during the last quarter. 91.91% of the stock is currently owned by hedge funds and other institutional investors.
Seres Therapeutics stock opened at $3.68 on Friday. The firm has a market cap of $276.55 million, a PE ratio of -1.51 and a beta of 1.82. Seres Therapeutics has a 52-week low of $2.02 and a 52-week high of $8.39. The company’s 50 day moving average is $3.69 and its two-hundred day moving average is $3.38.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Featured Story: What are the economic characteristics of a bear market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.